By: Claire Bugos
Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new results from a three-year trial.
Claire Bugos is a Health News Reporter for Verywell. With a focus on providing accurate and up-to-date information, Claire covers a wide range of health topics including COVID-19 research, chronic conditions, treatments, and the latest developments in the medical field. Her goal is to empower readers with knowledge and help them make informed decisions about their health.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Claire Bugos' coverage primarily focuses on healthcare and pharmaceutical topics, with an emphasis on citing data and press releases. She appears to value evidence-based reporting and may be more responsive to pitches that include scientific studies, clinical trial results, or expert commentary from reputable sources within the healthcare industry.
Given her focus on medical research, health issues, medications, and COVID-19 updates, Claire would likely be interested in receiving pitches related to breakthroughs in medical research or developments in the healthcare industry. Additionally, she might appreciate insights from professionals who can provide valuable perspectives on emerging health trends or innovative treatments.
It's important to note that Claire does not seem to have a specific geographic focus but rather covers global healthcare-related topics.
This information evolves through artificial intelligence and human feedback. Improve this profile .